536 related articles for article (PubMed ID: 15361374)
1. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement.
Alessandri C; Bombardieri M; Papa N; Cinquini M; Magrini L; Tincani A; Valesini G
Ann Rheum Dis; 2004 Oct; 63(10):1218-21. PubMed ID: 15361374
[TBL] [Abstract][Full Text] [Related]
2. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis.
De Rycke L; Verhelst X; Kruithof E; Van den Bosch F; Hoffman IE; Veys EM; De Keyser F
Ann Rheum Dis; 2005 Feb; 64(2):299-302. PubMed ID: 15166003
[TBL] [Abstract][Full Text] [Related]
3. IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis.
Vis M; Bos WH; Wolbink G; Voskuyl AE; Twisk JW; Van de Stadt R; Hamann D; Dijkmans BA; Lems WF
J Rheumatol; 2008 Mar; 35(3):425-8. PubMed ID: 18322974
[TBL] [Abstract][Full Text] [Related]
4. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.
Chen HA; Lin KC; Chen CH; Liao HT; Wang HP; Chang HN; Tsai CY; Chou CT
Ann Rheum Dis; 2006 Jan; 65(1):35-9. PubMed ID: 15975966
[TBL] [Abstract][Full Text] [Related]
5. Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody.
Mikuls TR; O'Dell JR; Stoner JA; Parrish LA; Arend WP; Norris JM; Holers VM
Arthritis Rheum; 2004 Dec; 50(12):3776-82. PubMed ID: 15593224
[TBL] [Abstract][Full Text] [Related]
6. Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis.
Bruns A; Nicaise-Roland P; Hayem G; Palazzo E; Dieudé P; Grootenboer-Mignot S; Chollet-Martin S; Meyer O
Joint Bone Spine; 2009 May; 76(3):248-53. PubMed ID: 19208451
[TBL] [Abstract][Full Text] [Related]
7. [Cyclic citrullinated peptide antibodies (anti-CCP) together with some other parameters used for serologic diagnosis of rheumatoid arthritis].
Us D; Gülmez D; Hasçelik G
Mikrobiyol Bul; 2003; 37(2-3):163-70. PubMed ID: 14593899
[TBL] [Abstract][Full Text] [Related]
8. Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis.
Nielen MM; van der Horst AR; van Schaardenburg D; van der Horst-Bruinsma IE; van de Stadt RJ; Aarden L; Dijkmans BA; Hamann D
Ann Rheum Dis; 2005 Aug; 64(8):1199-204. PubMed ID: 15640269
[TBL] [Abstract][Full Text] [Related]
9. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.
Lequerré T; Jouen F; Brazier M; Clayssens S; Klemmer N; Ménard JF; Mejjad O; Daragon A; Tron F; Le Loët X; Vittecoq O
Rheumatology (Oxford); 2007 Mar; 46(3):446-53. PubMed ID: 16899502
[TBL] [Abstract][Full Text] [Related]
10. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.
Quartuccio L; Fabris M; Salvin S; Atzeni F; Saracco M; Benucci M; Cimmino M; Morassi P; Masolini P; Pellerito R; Cutolo M; Puttini PS; De Vita S
Rheumatology (Oxford); 2009 Dec; 48(12):1557-9. PubMed ID: 19789202
[TBL] [Abstract][Full Text] [Related]
11. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment.
Bobbio-Pallavicini F; Alpini C; Caporali R; Avalle S; Bugatti S; Montecucco C
Arthritis Res Ther; 2004; 6(3):R264-72. PubMed ID: 15142273
[TBL] [Abstract][Full Text] [Related]
12. Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis.
Toubi E; Kessel A; Slobodin G; Boulman N; Pavlotzky E; Zisman D; Rozenbaum M; Rosner I
Ann Rheum Dis; 2007 Jun; 66(6):818-20. PubMed ID: 17148544
[TBL] [Abstract][Full Text] [Related]
13. Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis.
Greiner A; Plischke H; Kellner H; Gruber R
Ann N Y Acad Sci; 2005 Jun; 1050():295-303. PubMed ID: 16014545
[TBL] [Abstract][Full Text] [Related]
14. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis.
Braun-Moscovici Y; Markovits D; Zinder O; Schapira D; Rozin A; Ehrenburg M; Dain L; Hoffer E; Nahir AM; Balbir-Gurman A
J Rheumatol; 2006 Mar; 33(3):497-500. PubMed ID: 16511906
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis.
Matsui T; Shimada K; Ozawa N; Hayakawa H; Hagiwara F; Nakayama H; Sugii S; Ozawa Y; Tohma S
J Rheumatol; 2006 Dec; 33(12):2390-7. PubMed ID: 16924694
[TBL] [Abstract][Full Text] [Related]
16. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
[TBL] [Abstract][Full Text] [Related]
17. [The role of anti-cyclic citrullinated peptide (anti-CCP) antibodies in serologic diagnosis and evaluation of disease activity in rheumatoid arthritis].
Aridoğan BC; Kaya S; Savaş S; Cetin ES; Akkuş S; Demirci M
Mikrobiyol Bul; 2008 Oct; 42(4):669-74. PubMed ID: 19149089
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis.
Vallbracht I; Rieber J; Oppermann M; Förger F; Siebert U; Helmke K
Ann Rheum Dis; 2004 Sep; 63(9):1079-84. PubMed ID: 15308516
[TBL] [Abstract][Full Text] [Related]
19. The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study.
Klaasen R; Cantaert T; Wijbrandts CA; Teitsma C; Gerlag DM; Out TA; de Nooijer MJ; Baeten D; Tak PP
Rheumatology (Oxford); 2011 Aug; 50(8):1487-93. PubMed ID: 21454308
[TBL] [Abstract][Full Text] [Related]
20. Anti-cyclic citrullinated peptide antibodies distinguish hepatitis B virus (HBV)-associated arthropathy from concomitant rheumatoid arthritis in patients with chronic HBV infection.
Lim MK; Sheen DH; Lee YJ; Mun YR; Park M; Shim SC
J Rheumatol; 2009 Apr; 36(4):712-6. PubMed ID: 19286846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]